Table 4.
Clinical outcomes after rituximab, via the LP or RA protocols, or intravenous immunoglobulin.
| Protocol (# patients) | CR % (n) | CR off % (n) | CR on % (n) | PR % (n) | Nonresponse/failure % (n) | Relapse % (n) | Infection % (n) | Mean follow-up, months (range) |
|---|---|---|---|---|---|---|---|---|
| RTX (n=76) § | 63.2% (48)* | 28.9% (22) | 31.6% (24) | 28.9% (22) |
2.6% (2) | 39.5% (30) | 19.7% (15) | 22.1 (2-84) |
| IVIg (n=8)** | 62.5% (5) | None | 50% (4) |
25% (2) |
None | None | None | 24.8 (6-51) |
| p-value | NS | p<0.0001 | NS | NS | p<0.0001 | p<0.0001 | p<0.0001 | NS |
§ Clinical outcomes were not reported in five out of 81 patients treated with RTX via the RA or LP protocols.
*The total number of patients reaching CR (48) included patients reaching CR-off and on therapy. In two reports, the authors of those reports did not specify if the patient was on or off therapy, and were thus included in the total value reaching CR.
**One patient only had clinical improvement, without meeting criteria for either CR or PR, and was thus not presented here.
CR, complete remission; CR off, clinical remission off-therapy; CR on, clinical remission on-therapy; PR, partial remission; RA protocol, rheumatoid arthritis protocol; LP, lymphoma protocol; NS, not statistically significant.